IMS Health Holdings Inc

IMS Health — Q4 2015 Earnings Presentation

20 slides from IMS Health's earnings presentation, Feb 3, 2016

  1. Slide 1: IMS Health Q4 2015 Earnings Call

    IMS Health Q4 2015 Earnings Call February 3, 2016 0

  2. Slide 2: Legal

    Legal This presentation should be viewed in conjunction with IMS Health’s Q4 2015 earnings call Safe Harbor Statement This presentation Thi t ti includes i l d “forward-looking “f d l ki statements”, t t t ” including i l di statements t t t regarding di future f t fi financial i l and d operating t

  3. Slide 3: 4th Quarter Results

    4th Quarter Results $M Revenue Adjusted EBITDA +28.3% 28 3% +16.8% 16 8% @ CFx @ CFx $812 $232 $678 $214 Q4 2015 Q4 2014 Q4 2015 Q4 2014 Note: Dollars are at actual foreign exchange rates. CFx is constant currency. EBITDA is “Adjusted EBITDA” as calculated in the appendix of this presentation 2 IMS

  4. Slide 4: 4th Quarter Offering Revenue

    4th Quarter Offering Revenue Offering 4th Quarter Versus Prior Year Constant $M 2015 2014 Reported Currency Information $382 $366 12.4% 4.2% Technology Services $430 $312 47.3% 37.9% Total $812 $678 28.3% 19.7% Note: Dollars are at actual foreign exchange rates 3 IMS Health Confidential

  5. Slide 5: 4th Quarter Geographic Revenue

    4th Quarter Geographic Revenue Geography 4th Quarter Versus Prior Year Constant $M 2015 2014 Reported Currency Developed Markets $689 $571 27.7% 20.6% Emerging Markets $123 $107 32.0% 14.8% Total $812 $678 28.3% 19.7% Note: Dollars are at actual foreign exchange rates Prior year adjusted to conform

  6. Slide 6: 4th Quarter EBITDA

    4th Quarter EBITDA 4th Quarter Versus Prior Year Constant $M 2015 2014 Reported Currency Adjusted EBITDA (1) $232 $214 16.8% 8.4% Adjusted EBITDA margin 28.6% 31.6% (285) bps (298) bps Note: Dollars are at actual foreign exchange rates (1) See reconciliations of non-GAAP items in appendix 5 IMS Heal

  7. Slide 7: 4th Quarter P&L

    4th Quarter P&L At reported FX rates $M (except per share data) 2015 2014 Net Income $29 $8 Diluted Earnings per Share $0.09 $0.03 Adjusted Net Income (1) $125 $125 Adjusted Diluted Earnings per Share (1) $0.37 $0.36 (1) See reconciliations of non-GAAP items in appendix 6 IMS Health Confidential

  8. Slide 8: Full-Year Revenue

    Full-Year Revenue Offering Full-year Versus Prior Year Constant $M 2015 2014 Reported Currency Information $1,483 $1,515 8.4% (2.1%) Technology Services $1 438 $1,438 $1 126 $1,126 37 7% 37.7% 27 7% 27.7% Total $2,921 $2,641 21.0% 10.6% Geography Full-year Versus Prior Year Developed Markets $2,448

  9. Slide 9: Full-Year P&L

    Full-Year P&L $M (except per share data) 2015 2014 Adjusted EBITDA (1) $886 $878 Adjusted EBITDA margin 30.3% 33.2% Net Income / (Loss) $417 $(189) Diluted Earnings / (Loss) per Share $1 23 $1.23 $(0 59) $(0.59) Adjusted Net Income (1) $515 $454 Adjusted Diluted EPS (1) $1.52 $1.37 (1) See reconcili

  10. Slide 10: 4th Quarter Balance Sheet Items & Metrics

    4th Quarter Balance Sheet Items & Metrics $M 2015 2014 Cash & Cash Equivalents q $396 $390 Principal Balance of Debt (1) $4,266 $3,816 Net Debt $3,870 $3,426 Gross Leverage Ratio 4.8x 4.3x Net Cash Provided by Operating Activities $164 $147 Capital Expenditures and Additions to Deferred $67 $38 Soft

  11. Slide 11: 2016 Guidance

    2016 Guidance Full-Year 2016 Revenue Growth Constant Currency 10 - 12% Reported (1) 7.5 - 9.5% Adjusted EBITDA Growth Constant Currency 7.5 - 9.5% Reported (1) 6 - 8% Adjusted Net Income Growth Constant Currency 6.5 - 8.5% Reported (1) 0.5 - 2.5% Adjusted Diluted EPS Constant Currency 8.5 - 10.5% Re

  12. Slide 12: Adjusted EBITDA Margins

    Adjusted EBITDA Margins * Estimated 2015 - 2016 2015 Adj. Product Growth Cost Acquisition 2016 Adj. EBITDA Mix * Investments Reductions Impact * EBITDA Margin Margin 11 IMS Health Confidential

  13. Slide 13: Q1 2016 Guidance

    Q1 2016 Guidance Q1 2016 Revenue Growth Constant Currency 21 - 23% Reported (1) 17 - 19% Adjusted EBITDA Growth Constant Currency 6.5 - 8.5% Reported (1) 4.5 - 6.5% Adjusted Net Income Growth Constant Currency (1) - 1% Reported (1) (5) - (7)% Adjusted Diluted EPS Constant Currency 2.5 - 4.5% Reporte

  14. Slide 14: Q&A

    Q&A 13

  15. Slide 15: Appendix: Non-GAAP Financial Measures

    Appendix: A di Non-GAAP N GAAP Financial Measures 14

  16. Slide 16: Net Income (Loss) to Adjusted EBITDA

    Net Income (Loss) to Adjusted EBITDA Three Months Ended Twelve Months Ended December 31, December 31, (in millions) 2015 2014 2015 2014 Net Income (Loss) $ 29 $ 8 $ 417 $ (189) Provision for (benefit from) income taxes 19 45 (200) (96) Oth (income) Other (i ) loss, l nett (3) (5) (19) 276 Interest e

  17. Slide 17: Net Income (Loss) to Adjusted Net Income & Per Share Data

    Net Income (Loss) to Adjusted Net Income & Per Share Data Three Months Ended Twelve Months Ended December 31, December 31, (in millions, except per share data) 2015 2014 2015 2014 Net Income (Loss) $ 29 $ 8 $ 417 $ (189) Provision for (benefit from) income taxes 19 45 (200) (96) Amortization associa

  18. Slide 18: Unlevered Free Cash Flow

    Unlevered Free Cash Flow Three Months Ended Twelve Months Ended December 31, December 31, (in millions) 2015 2014 2015 2014 Net Cash Provided by Operating Activities $ 164 $ 147 $ 490 $ 110 Capital expenditures (23) (13) (52) (72) Additions to computer software (44) (25) (131) (95) Free Cash Flow $

  19. Slide 19: Gross Leverage Ratio

    Gross Leverage Ratio December 31, 2015 (in millions) Gross Debt $ 4,266 Adjusted EBITDA (for the twelve months ended December 31, 2015) $ 886 Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA) 4.8x 18 IMS Health Confidential

  20. Slide 20: Non-GAAP Adjustments By Income Statement Line Items

    Non-GAAP Adjustments By Income Statement Line Items Three Months Ended Twelve Months Ended December 31, December 31, (in millions) 2015 2014 2015 2014 Non-GAAP adjustments included in: Operating O ti costs t off information, i f ti exclusive l i off depreciation d i ti $ 1 $ 2 $ 4 $ 21 and amortizat

IMS Health — Q4 2015 Earnings Presentation on 6ix